ClinicalTrials.gg
RecruitingNCT06057675Updated Sep 9, 2026

Tranexamic Acid in Nasal Mohs Reconstruction

A Phase 2 interventional study of Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine) and Control (1% lidocaine with 1:100,000 epinephrine) in Postoperative Bleeding and Skin Cancer Face, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Vanderbilt University Medical Center · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Postoperative Hemorrhage with a site in United States — 9 open to participants now, 9 under way, 2 of them phase 3. Postoperative Hemorrhage · United States.

Planned enrollment
15th of 28
100 · median 108
Started
2024
the only one that year
Phase 2
3 of 32
2 open now
Registered
27th of 32
by date
Lead sponsor
2 of 32
Vanderbilt University Medical Center

Among the 32 studies in Postoperative Hemorrhage with a site in United States, this one is the 15th largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 2, and was the 27th registered.

Postoperative Hemorrhage

135 studies on the registry are indexed under Postoperative Hemorrhage; 31 are open to participants now.

Browse Postoperative Hemorrhage studies →

Open to participants now

9 of the 32 studies in Postoperative Hemorrhage with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Postoperative Hemorrhage studies recruiting now, 11 (65%) set no upper age limit and 4 (24%) stop at 75 or younger; 2 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Postoperative Hemorrhage with a site in United States, or all of them as a file.
02

Study summary

This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.

Read the detailed description

Tranexamic acid (TXA) is an antifibrinolytic agent that acts to decrease bleeding by stabilizing the fibrin matrix involved in the clotting cascade. The use of TXA has been extensively described in the literature to prevent exsanguination in trauma and in various surgical procedures, as well as for heavy menstrual bleeding and epistaxis. Studies have suggested administration of TXA may improve outcomes in aesthetic surgery as well, specifically regarding intraoperative bleeding and postoperative ecchymosis and hematoma formation. TXA may be administered systemically, via IV or PO routes, or locally, via topical application or subcutaneous injection. Local administration allows for similar benefits with minimal risk of systemic effects.

Following facial Mohs reconstruction patients often experience surgical site ecchymosis and swelling, which may be distressing, painful, prolong healing, and result in increased healthcare utilization. Other complications include hematoma, wound dehiscence, and suboptimal scarring. Given the growing body of literature demonstrating the benefits of TXA in surgical bleeding outcomes, TXA may also be beneficial in improving postoperative Mohs complications and patient satisfaction.

To date, no studies have investigated the use of perioperative TXA specifically in nasal Mohs reconstruction. This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.

03

Conditions studied

  • Postoperative Bleeding
  • Skin Cancer Face

Keywords

  • Tranexamic Acid
  • Mohs Reconstruction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults at least 18 years of age undergoing local flap reconstruction (bilobe flap, note flap dorsal nasal flap, advancement flap) of a nasal defect following Mohs micrographic surgery. Reconstructive procedures will be performed by Drs. Yang or Patel in the division of Facial Plastic Surgery in the Department of Otolaryngology, Head and Neck Surgery at Vanderbilt University Medical Center.
  2. No other facial plastic procedure or sinus surgery performed simultaneously.
  3. Lack of all the below exclusion criteria.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to TXA
  2. Intracranial bleeding
  3. Known defective color vision
  4. History of venous or arterial thromboembolism
  5. History of coagulation disorder
  6. Active thromboembolic disease
  7. Severe renal impairment (diagnosis of chronic kidney disease)
  8. History of acute myocardial infarction
  9. History of stroke
  10. History of seizure
  11. History of liver failure
  12. Preoperative lab results indicating thrombocytopenia ( \<150,000), increased bleeding risk (PT over 45, over 1.2).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Control

    The control arm will receive the current standard of care. Before incision, local anesthetic (1% lidocaine with 1:100,000 epinephrine) will be injected subcutaneously into the surgical site. The surgical team will inject approximately 0.8mL per square centimeter of the surgical site area (defect area and undermined tissue area).

    Drug: Control (1% lidocaine with 1:100,000 epinephrine)

  • Experimental
    Experimental

    The experimental arm will receive local anesthetic (1% lidocaine with 1:100,000 epinephrine) and TXA (1g/10mL) in a 9:1 volume ratio. This will be injected subcutaneously into the surgical site. The surgical team will inject approximately 0.8mL per square centimeter of the surgical site area (defect area and undermined tissue area).

    Drug: Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine)

Interventions

  • DrugTreatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine)

    Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine) and tranexamic acid (1g/10mL), mixed in a 9:1 volume ratio.

    Also known as: Tranexamic Acid

  • DrugControl (1% lidocaine with 1:100,000 epinephrine)

    Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine)

    Also known as: Standard of Care

06

What researchers measure

Primary outcomes

  1. Surgical site swelling and bruising (surgeon)

    Photos will be taken by a research team member at the first postoperative clinic visit and then analyzed and graded by a blinded reviewer for measures including surgical site bruising and swelling. Surgical site swelling and bruising will be graded on a 4 point scale, with 0 indicating no swelling and bruising and 3 indicating significant swelling and bruising.

    Time frame: One week

  2. Surgical site swelling and bruising (patient)

    Subjective measures of patient perceived swelling and bruising will be collected via a patient completed survey given at the first postoperative clinic visit. Surgical site swelling and bruising will be graded on a 4 point scale, with 0 indicating no swelling and bruising and 3 indicating significant swelling and bruising.

    Time frame: One week

  3. Intraoperative bleeding

    Intraoperative bleeding will be assessed using the validated Boezaart Bleeding scale (6 point scale, with 0 indicating no bleeding/cadaveric conditions and 5 indicating severe bleeding/constant suctioning required). Values will be assigned by the attending surgeon and recorded by the research team.

    Time frame: Intraoperative

  4. Intraoperative bleeding

    Attending surgeon will score the approximate percent blood saturation of each surgical sponge used in the case. Values from each sponge will be added together for a total cumulative value, with a higher cumulative value indicating a greater amount of intraoperative bleeding.

    Time frame: Intraoperative

Secondary outcomes

  1. Postoperative pain

    Subjective measure of patient perceived pain will be collected via a patient completed survey given at the first postoperative clinic visit. Responses will be graded on a 5 point scale, with 1 indicating "no pain" and 5 indicating "severe pain."

    Time frame: One week

  2. Postoperative pain

    Objective measure of pain control will also be collected with an estimate of total amount of opioid pain medication used in the first week after surgery.

    Time frame: One week

  3. Postoperative patient satisfaction

    Subjective measure of postoperative patient satisfaction will be collected via a patient completed survey given at the first postoperative clinic visit. Responses will be graded on a 5 point scale, with 1 indicating "very dissatisfied" and 5 indicating "very satisfied."

    Time frame: One week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There are no current plans to make IPD available to other researchers. However, if information is made available, to protect patient privacy, patient names will not be released.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Aug 2027, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2023
First posted
Sep 28, 2023
StartActual
Mar 19, 2024
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06057675
Responsible party
Priyesh Patel (Asst. Professor of Otolaryngology, Vanderbilt University Medical Center) — Principal investigator
First posted
Sep 28, 2023
Start date
Mar 19, 2024
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 9, 2026

Study contacts

Connie Ma, MD
Contact
connie.ma@vumc.org
2815366877
Priyesh Patel, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion